Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CEL | P19835 | 2/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.31 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29986193 | 1.00 | TDP1 (0.40) | TDP1CELTDO2GCGRGRM2 | |
| SCHEMBL29987339 | 0.98 | TDP1 (0.39) | TDP1CELTDO2GCGRGRM2 | |
| SCHEMBL10845597 | 0.98 | TDP1 (0.39) | TDP1CELTDO2GCGRGRM2 | |
| SCHEMBL31524176 | 0.96 | TDP1 (0.40) | TDP1CELPSMB5 | |
| SCHEMBL30833923 | 0.96 | TDP1 (0.40) | TDP1CELPSMB5 | |
| SCHEMBL2647857 | 0.96 | TDP1 (0.40) | TDP1CELPSMB5 | |
| SCHEMBL2662122 | 0.94 | TDP1 (0.36) | TDP1CELGCGRGRM2PTGDR | |
| SCHEMBL1188150 | 0.91 | TDP1 (0.43) | TDP1ALDH1A1 | |
| SCHEMBL29919389 | 0.91 | TDP1 (0.43) | TDP1ALDH1A1 | |
| SCHEMBL8111724 | 0.90 | TDP1 (0.36) | TDP1CELALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089582-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | KPC PHARMACEUTICALS INC (CN) | 2023-03-23 | — | — | US | disclosed |
| EP-4083024-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | KPC Pharmaceuticals, Inc. (CN) | 2022-11-02 | — | — | EP | disclosed |
| CN-113278013-B | 2, 6-disubstituted 1,2, 4-triazine-3, 5-diketone compound and preparation method and application thereof | 昆药集团股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| EP-3759096-B1 | CD73 INHIBITORS | LILLY CO ELI (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113278013-A | 2, 6-disubstituted 1,2, 4-triazine-3, 5-diketone compound and preparation method and application thereof | 昆药集团股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-11028074-B2 | CD73 inhibitors | ELI LILLY AND COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2021104288-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 昆药集团股份有限公司 | 2021-06-03 | — | — | WO | disclosed |
| WO-2021104288-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 昆药集团股份有限公司 | 2021-06-03 | — | — | WO | disclosed |
| US-20210002257-A1 | CD73 INHIBITORS | ELI LILLY AND COMPANY | 2021-01-07 | — | — | US | disclosed |
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| CN-104903320-A | Nitrogen-containing heterocylic compound or salt thereof | FUJIFILM CORP | 2015-09-09 | — | — | CN | disclosed |
| WO-2014109414-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | 富士フイルム株式会社 (JP) | 2014-07-17 | — | — | WO | disclosed |
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-0915875-B1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2003-04-09 | — | — | EP | disclosed |
| US-6255305-B1 | PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| EP-0781283-B1 | TRIAZOLOPYRIDAZINES PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-0781283-A1 | TRIAZOLOPYRIDAZINES PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Takeda Chemical Industries, Ltd. (JP) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008496-A1 | TRIAZOLOPYRIDAZINES PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-21 | — | — | WO | disclosed |
| US-5482939-A | ANTI-PLATELET ACTIVATING FACTOR ACTIVITIES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-09 | — | — | US | disclosed |
| US-4628088-A | Preparation of substituted pyridazines | ELI LILLY AND COMPANY (US) | 1986-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028074-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | TDP1 256/4885CEL 4129/4885TDO2 265/4885 |
| US-20230089582-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | THRB, THRA, TSHR | TDP1 1882/4885CEL 813/4885TDO2 706/4885 |
| US-20210002257-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | TDP1 256/4885CEL 4129/4885TDO2 265/4885 |
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | TDP1 1364/4885CEL 2611/4885TDO2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.